Cargando…
Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status
The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2. The U.S. government’s Clinical Laboratory Improvement Amendments (CLIA) of 1988 regulates the studies that a clinical diagnostic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451421/ https://www.ncbi.nlm.nih.gov/pubmed/34260276 http://dx.doi.org/10.1128/JCM.01167-21 |
_version_ | 1784569840261922816 |
---|---|
author | Peaper, David R. Rhoads, Daniel D. Sullivan, Kaede V. Couturier, Marc R. Humphries, Romney M. Martin, Isabella W. Nolte, Frederick S. Rowlinson, Marie-Claire She, Rosemary C. Simner, Patricia J. Theel, Elitza S. Wojewoda, Christina M. |
author_facet | Peaper, David R. Rhoads, Daniel D. Sullivan, Kaede V. Couturier, Marc R. Humphries, Romney M. Martin, Isabella W. Nolte, Frederick S. Rowlinson, Marie-Claire She, Rosemary C. Simner, Patricia J. Theel, Elitza S. Wojewoda, Christina M. |
author_sort | Peaper, David R. |
collection | PubMed |
description | The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2. The U.S. government’s Clinical Laboratory Improvement Amendments (CLIA) of 1988 regulates the studies that a clinical diagnostic laboratory needs to perform for an IVD before placing it into use. Until recently, the FDA has authorized the marketing of SARS-CoV-2 IVDs exclusively through the Emergency Use Authorization (EUA) pathway. The regulatory landscape continues to evolve, and IVDs will eventually be required to pass through conventional non-EUA FDA review pathways once the emergency declaration is terminated, in order to continue to be marketed as an IVD in the United States. When FDA regulatory status of an IVD changes or is anticipated to change, the laboratory should review manufacturer information and previously performed internal verification studies to determine what, if any, additional studies are needed before implementing the non-EUA version of the IVD in accordance with CLIA regulations. Herein, the College of American Pathologists’ Microbiology Committee provides guidance for how to approach regulatory considerations when an IVD is converted from EUA to non-EUA status. |
format | Online Article Text |
id | pubmed-8451421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-84514212021-10-04 Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status Peaper, David R. Rhoads, Daniel D. Sullivan, Kaede V. Couturier, Marc R. Humphries, Romney M. Martin, Isabella W. Nolte, Frederick S. Rowlinson, Marie-Claire She, Rosemary C. Simner, Patricia J. Theel, Elitza S. Wojewoda, Christina M. J Clin Microbiol Commentary The U.S. Food & Drug Administration (FDA) regulates the marketing of manufacturers’ in vitro diagnostic tests (IVDs), including assays for the detection of SARS-CoV-2. The U.S. government’s Clinical Laboratory Improvement Amendments (CLIA) of 1988 regulates the studies that a clinical diagnostic laboratory needs to perform for an IVD before placing it into use. Until recently, the FDA has authorized the marketing of SARS-CoV-2 IVDs exclusively through the Emergency Use Authorization (EUA) pathway. The regulatory landscape continues to evolve, and IVDs will eventually be required to pass through conventional non-EUA FDA review pathways once the emergency declaration is terminated, in order to continue to be marketed as an IVD in the United States. When FDA regulatory status of an IVD changes or is anticipated to change, the laboratory should review manufacturer information and previously performed internal verification studies to determine what, if any, additional studies are needed before implementing the non-EUA version of the IVD in accordance with CLIA regulations. Herein, the College of American Pathologists’ Microbiology Committee provides guidance for how to approach regulatory considerations when an IVD is converted from EUA to non-EUA status. American Society for Microbiology 2021-09-20 /pmc/articles/PMC8451421/ /pubmed/34260276 http://dx.doi.org/10.1128/JCM.01167-21 Text en Copyright © 2021 American Society for Microbiology. https://doi.org/10.1128/ASMCopyrightv2All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Commentary Peaper, David R. Rhoads, Daniel D. Sullivan, Kaede V. Couturier, Marc R. Humphries, Romney M. Martin, Isabella W. Nolte, Frederick S. Rowlinson, Marie-Claire She, Rosemary C. Simner, Patricia J. Theel, Elitza S. Wojewoda, Christina M. Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title | Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title_full | Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title_fullStr | Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title_full_unstemmed | Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title_short | Considerations from the College of American Pathologists for Implementation of an Assay for SARS-CoV-2 Testing after a Change in Regulatory Status |
title_sort | considerations from the college of american pathologists for implementation of an assay for sars-cov-2 testing after a change in regulatory status |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451421/ https://www.ncbi.nlm.nih.gov/pubmed/34260276 http://dx.doi.org/10.1128/JCM.01167-21 |
work_keys_str_mv | AT peaperdavidr considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT rhoadsdanield considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT sullivankaedev considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT couturiermarcr considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT humphriesromneym considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT martinisabellaw considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT noltefredericks considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT rowlinsonmarieclaire considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT sherosemaryc considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT simnerpatriciaj considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT theelelitzas considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus AT wojewodachristinam considerationsfromthecollegeofamericanpathologistsforimplementationofanassayforsarscov2testingafterachangeinregulatorystatus |